Prednisolone and Gentamicin
Medically reviewed on September 10, 2018
(pred NIS oh lone & jen ta MYE sin)
- Gentamicin and Prednisolone
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Pred-G: Prednisolone acetate 0.6% and gentamicin sulfate 0.3% (3.5 g) [contains edetate disodium, polysorbate 80]
Pred-G: Prednisolone acetate 1% and gentamicin sulfate 0.3% (5 mL) [contains benzalkonium chloride]
Brand Names: U.S.
- Antibiotic/Corticosteroid, Ophthalmic
Gentamicin: Interferes with bacterial protein synthesis by binding to 30S ribosomal subunits resulting in a defective bacterial cell membrane
Prednisolone: Reduces inflammation by inhibiting edema, leukocyte migration, fibrin deposition, capillary proliferation and dilation, collagen deposition and scar formation.
Use: Labeled Indications
Inflammatory ocular conditions and superficial ocular infections: Treatment of steroid responsive inflammatory ocular conditions where either a superficial bacterial ocular infection or the risk of bacterial ocular infection exists
Hypersensitivity to gentamicin, prednisolone, other corticosteroids, or any component of the formulation; viral disease of the cornea and conjunctiva (including epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella); mycobacterial or fungal infection of the eye
Inflammatory conditions and superficial ocular infections: Ophthalmic:
Ointment: Apply 1/2 inch ribbon into the conjunctival sac of the affected eye(s) 1 to 3 times per day
Suspension: Instill 1 drop into the conjunctival sac of the affected eye(s) 2 to 4 times per day; during the initial 24 to 48 hours, the dosing frequency may be increased if necessary up to 1 drop every hour
Note: If signs and symptoms do not improve after 2 days of treatment, the patient should be re-evaluated.
Refer to adult dosing.
Dosing: Renal Impairment
There are no dosage adjustments provided in the manufacturer's labeling
Dosing: Hepatic Impairment
There are no dosage adjustments provided in the manufacturer's labeling
Ophthalmic: Note: Contact lenses should not be worn during therapy. Do not touch the bottle or tube tip to eyelid(s) or any other surface.
Ointment: Apply into pocket between eyeball and lower lid; patient should look downward before closing eye.
Suspension: Shake well before using. Tilt head back, instill into the conjunctival sac and close eye(s). Apply light finger pressure on lacrimal sac for 1 minute following instillation.
Ointment: Store at 15°C to 25°C (59°F to 77°F).
Suspension: Store at 15°C to 25°C (59°F to 77°F). Avoid excessive heat (≥40°C [104°F]). Do not freeze.
Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. Monitor therapy
Nonsteroidal Anti-Inflammatory Agents (Ophthalmic): May enhance the adverse/toxic effect of Corticosteroids (Ophthalmic). Healing of ophthalmic tissue during concomitant administration of ophthalmic products may be delayed. Monitor therapy
Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. Monitor therapy
Frequency not defined.
Dermatologic: Contact dermatitis, skin rash
Hypersensitivity: Angioedema, hypersensitivity reaction
Ophthalmic: Allergic conjunctivitis, blurred vision, burning sensation of eyes, eye discharge, eye irritation, eye pain, foreign body sensation of eye, increased lacrimation, ocular edema, ocular hyperemia, stinging of eyes, superficial punctate keratitis, visual impairment
Concerns related to adverse effects:
• Infection: Steroids may mask infection or enhance existing ocular infection (including herpes simplex); prolonged use may result in secondary bacterial or fungal superinfection due to immunosuppression.
• Ocular effects: Ocular irritation and punctate keratitis have occurred. Prolonged use of corticosteroids may result in glaucoma; damage to the optic nerve, defects in visual acuity and fields of vision, corneal and scleral thinning (leading to perforation), and posterior subcapsular cataract formation may occur.
• Glaucoma: Use with caution; monitor intraocular pressure frequently.
• Ocular herpes simplex: Use with extreme caution; frequent slit lamp microscopy is recommended.
• Cataract surgery patients: Use following cataract surgery may delay healing or increase the incidence of bleb formation.
• Contact lens wearers: Some products contain benzalkonium chloride which may be absorbed by soft contact lenses; contact lenses should not be worn during treatment of ophthalmologic infections.
Dosage form specific issues:
• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson,2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.
• Appropriate use: For ophthalmic use only. Do not inject subconjunctivally or introduce into the anterior chamber of the eye. A maximum of 20 mL of suspension or a maximum of 8 g of ointment should be prescribed initially; patients should be re-evaluated (eg, intraocular pressure and exams using magnification and fluorescein staining, where appropriate) prior to additional refills. Use >10 days should include routine monitoring of intraocular pressure.
Pregnancy Risk Factor
Animal reproduction studies have not been conducted with this combination. See individual agents.
• Discuss specific use of drug and side effects with patient as it relates to treatment. (HCAHPS: During this hospital stay, were you given any medicine that you had not taken before? Before giving you any new medicine, how often did hospital staff tell you what the medicine was for? How often did hospital staff describe possible side effects in a way you could understand?)
• Patient may experience watery eyes, blurred vision, foreign body sensation in eye, change in taste, burning, or stinging. Have patient report immediately to prescriber vision changes, eye pain, or severe eye irritation (HCAHPS).
• Educate patient about signs of a significant reaction (eg, wheezing; chest tightness; fever; itching; bad cough; blue skin color; seizures; or swelling of face, lips, tongue, or throat). Note: This is not a comprehensive list of all side effects. Patient should consult prescriber for additional questions.
Intended Use and Disclaimer: Should not be printed and given to patients. This information is intended to serve as a concise initial reference for health care professionals to use when discussing medications with a patient. You must ultimately rely on your own discretion, experience, and judgment in diagnosing, treating, and advising patients.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about gentamicin/prednisolone ophthalmic
- Gentamicin/prednisolone ophthalmic Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- Drug class: ophthalmic steroids with anti-infectives
- Gentamicin and prednisolone ophthalmic
- Prednisolone and Gentamicin Eye Drops
- Prednisolone and Gentamicin Eye Ointment
Other brands: Pred-G